Antiplatelet Conversion - P2Y12 Inhibitor Switching • Clopidogrel (Plavix) • Prasugrel (Effient) • Ticagrelor (Brilinta) Clopidogrel and prasugrel are both competitive antagonists that bind to the active site of the P2Y12 receptor. Ticagrelor, a noncompetitive antagonist, binds to the allosteric site, causing a conformational change in the active site and thus preventing the binding of clopidogrel and prasugrel • Irreversible inhibitor: clopidogrel and prasugrel • Reversible inhibitor: ticagrelor by Dr. Laila Najia @laila_najia via ACCP Cardiology PRN @accpcardprn #Antiplatelet #Conversion #P2Y12 #Inhibitor #Switching #pharmacology #cardiology
